We have obtained encouraging results in mouse bladder carcinoma using CpG and agonistic anti-OX40 treatment, which provides a basis for further research with TLR agonists and antagonists, which are able to direct the immune response to the cellular pathway. This evidence concerns the gene TNFRSF4 and urinary bladder carcinoma.